Latest From Lupin Ltd.
Lupin’s management refer to multiple indicators suggesting the US generics segment is stabilizing. But traction for some key launches, delivering on pipeline promise, including in the inhalation space, and resolution of compliance issues could hold the key to lifting investor sentiment.
Sudarshan Jain, the new secretary general of the Indian Pharmaceutical Alliance and ex-Abbott managing director, wears many hats, including that of a senior advisor with a private equity advisory firm. He recounts having “survived in different cultures” in his career and outlines the priorities in his new role, amid continuing questions around generic quality.
Sterling Pharma Solutions has acquired a US facility and Olon has bought a plant from Sandoz, while Normon is investing €100m in manufacturing expansions.
Amneal gets a new CSO, Acino restructures its board under a new chair, the AAM adds an assistant general counsel and the British Biosimilars Association names a vice-chair, as well as other people movements from around the generics, biosimilars and value-added medicines industries.
- Controlled Release
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Lupin Laboratories
- Parent & Subsidiaries
- Lupin Ltd.
- Senior Management
Vinita Gupta, CEO
Ramesh Swaminathan , CFO
- Contact Info
Phone: (91) 22 6640 2222
B/4 Laxmi Towers, Bandra Kurla Complex
Mumbai, 400 051
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.